Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-05-21

Amgen Inc. (AMGN)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$24,693,120
Robert Bradway total, FY2025
50th
CEO pay percentile vs peers
160:1
CEO-to-median pay ratio
96.7%
Say-on-pay support, latest vote
Companies that benchmark against AMGN
22 companies name AMGN as a compensation peer

Each company listed discloses AMGN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AMGN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Robert Bradway$1,925,409$0$12,599,589$5,399,996$3,907,000$0$861,126$24,693,120
Chief Executive Officer and President
James Bradner1,238,580500,0003,359,7871,439,9651,675,0000426,5358,639,867
Executive Vice President, Research and Development
Peter Griffith1,223,99403,709,7451,589,9621,652,0000435,1868,610,887
Executive Vice President and Chief Financial Officer
Murdo Gordon1,233,18903,709,7451,589,9621,668,0000322,5758,523,471
Executive Vice President, Global Commercial Operations
David Reese1,306,72103,359,7871,439,9651,768,0000415,8358,290,308
Executive Vice President and Chief Technology Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Robert Bradway$24,693,120
James Bradner8,639,867
Peter Griffith8,610,887
Murdo Gordon8,523,4718,473,5008,242,811+49,971
David Reese8,290,308

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Murdo GordonEVP, Global Commercial Ops2026-05-02D830$330$273,751CommonForm 4 ↗
Matthew C. BuschVP, Finance & CAO2026-05-02D303309,895CommonForm 4 ↗
Nancy A. GrygielSVP & CCO2026-05-02D11633038,259CommonForm 4 ↗
Esteban SantosEVP, Operations2026-05-02D697330229,885CommonForm 4 ↗
Esteban SantosEVP, Operations2026-05-02D641330211,415CommonForm 4 ↗
Peter GriffithEVP & CFO2026-05-02D746330246,046CommonForm 4 ↗
Derek MillerSVP, Human Resources2026-05-02D19833065,304CommonForm 4 ↗
Robert A. BradwayDirector2026-05-02D2,426330800,143CommonForm 4 ↗
Robert A. BradwayDirector2026-05-02D2,631330867,756CommonForm 4 ↗
Nancy A. GrygielSVP & CCO2026-05-02D1,237324400,451CommonForm 4 ↗
Rachna KhoslaSVP, Business Development2026-05-02D11733038,589CommonForm 4 ↗
David ReeseEVP & Chief Technology Officer2026-05-02D746330246,046CommonForm 4 ↗
Jonathan P. GrahamEVP & Gen. Counsel & Sec.2026-05-02D610330201,190CommonForm 4 ↗
David ReeseEVP & Chief Technology Officer2026-05-02D687330226,586CommonForm 4 ↗
Derek MillerSVP, Human Resources2026-05-02D16733055,080CommonForm 4 ↗
Rachna KhoslaSVP, Business Development2026-05-02D10833035,621CommonForm 4 ↗
Peter GriffithEVP & CFO2026-05-02D687330226,586CommonForm 4 ↗
Jonathan P. GrahamEVP & Gen. Counsel & Sec.2026-05-02D647330213,394CommonForm 4 ↗
Murdo GordonEVP, Global Commercial Ops2026-05-02D763330251,653CommonForm 4 ↗
Matthew C. BuschVP, Finance & CAO2026-05-02D3833012,533CommonForm 4 ↗
Nancy A. GrygielSVP & CCO2026-05-02D12633041,557CommonForm 4 ↗
Derek MillerSVP, Human Resources2026-05-05A91000CommonForm 4 ↗
David ReeseEVP & Chief Technology Officer2026-05-05D454330149,634CommonForm 4 ↗
Esteban SantosEVP, Operations2026-05-05D427330140,735CommonForm 4 ↗
Charles M. Holley JrDirector2026-05-05A128.9500CommonForm 4 ↗
Murdo GordonEVP, Global Commercial Ops2026-05-05A23,7523307,828,422Derivative, Class A CommonForm 4 ↗
James BradnerEVP, Research and Development2026-05-05A3,33700CommonForm 4 ↗
Jonathan P. GrahamEVP & Gen. Counsel & Sec.2026-05-05D408330134,473CommonForm 4 ↗
Jonathan P. GrahamEVP & Gen. Counsel & Sec.2026-05-05A17,0223305,610,281Derivative, Class A CommonForm 4 ↗
Peter GriffithEVP & CFO2026-05-05D502330165,454CommonForm 4 ↗
Rachna KhoslaSVP, Business Development2026-05-05A50000CommonForm 4 ↗
Derek MillerSVP, Human Resources2026-05-05D12333040,540CommonForm 4 ↗
Derek MillerSVP, Human Resources2026-05-05A5,9383301,957,105Derivative, Class A CommonForm 4 ↗
David ReeseEVP & Chief Technology Officer2026-05-05A2,91200CommonForm 4 ↗
David ReeseEVP & Chief Technology Officer2026-05-05A19,0023306,262,869Derivative, Class A CommonForm 4 ↗
Esteban SantosEVP, Operations2026-05-05A2,73000CommonForm 4 ↗
Esteban SantosEVP, Operations2026-05-05A17,8143305,871,316Derivative, Class A CommonForm 4 ↗
S. Omar IshrakDirector2026-05-05A106.1900CommonForm 4 ↗
James BradnerEVP, Research and Development2026-05-05A21,7733307,176,163Derivative, Class A CommonForm 4 ↗
Robert A. BradwayDirector2026-05-05A12,13600CommonForm 4 ↗
Matthew C. BuschVP, Finance & CAO2026-05-05D5033016,480CommonForm 4 ↗
Murdo GordonEVP, Global Commercial Ops2026-05-05A3,64000CommonForm 4 ↗
Murdo GordonEVP, Global Commercial Ops2026-05-05D502330165,454CommonForm 4 ↗
Peter GriffithEVP & CFO2026-05-05A3,64000CommonForm 4 ↗
Peter GriffithEVP & CFO2026-05-05A23,7523307,828,422Derivative, Class A CommonForm 4 ↗
Nancy A. GrygielSVP & CCO2026-05-05A3,1673301,043,812Derivative, Class A CommonForm 4 ↗
Robert A. BradwayDirector2026-05-05A79,17633026,095,618Derivative, Class A CommonForm 4 ↗
James BradnerEVP, Research and Development2026-05-05D407330134,143CommonForm 4 ↗
Rachna KhoslaSVP, Business Development2026-05-05A3,2663301,076,441Derivative, Class A CommonForm 4 ↗
Michael V. DrakeDirector2026-05-05A79.6400CommonForm 4 ↗
Matthew C. BuschVP, Finance & CAO2026-05-05A45500CommonForm 4 ↗
Matthew C. BuschVP, Finance & CAO2026-05-05A2,969330978,553Derivative, Class A CommonForm 4 ↗
Robert A. BradwayDirector2026-05-05D1,702330560,962CommonForm 4 ↗
Jonathan P. GrahamEVP & Gen. Counsel & Sec.2026-05-05A2,60900CommonForm 4 ↗
Nancy A. GrygielSVP & CCO2026-05-05A48500CommonForm 4 ↗
Nancy A. GrygielSVP & CCO2026-05-05D7633025,049CommonForm 4 ↗
Rachna KhoslaSVP, Business Development2026-05-05D7933026,038CommonForm 4 ↗
Murdo GordonEVP, Global Commercial Ops2026-05-07D615331203,633CommonForm 4 ↗
David ReeseEVP & Chief Technology Officer2026-05-07D556331184,097CommonForm 4 ↗
Matthew C. BuschVP, Finance & CAO2026-05-07D4133113,576CommonForm 4 ↗
Rachna KhoslaSVP, Business Development2026-05-07D9333130,793CommonForm 4 ↗
Nancy A. GrygielSVP & CCO2026-05-07D8833129,138CommonForm 4 ↗
Robert A. BradwayDirector2026-05-07D2,079331688,378CommonForm 4 ↗
Derek MillerSVP, Human Resources2026-05-07D15133149,998CommonForm 4 ↗
Peter GriffithEVP & CFO2026-05-07D556331184,097CommonForm 4 ↗
James BradnerEVP, Research and Development2026-05-07D446331147,675CommonForm 4 ↗
Esteban SantosEVP, Operations2026-05-07D522331172,839CommonForm 4 ↗
Jonathan P. GrahamEVP & Gen. Counsel & Sec.2026-05-07D499331165,224CommonForm 4 ↗
Charles M. Holley JrDirector2026-05-19A66500CommonForm 4 ↗
Greg C. GarlandDirector2026-05-19A66500CommonForm 4 ↗
Brian J. DrukerDirector2026-05-19A66500CommonForm 4 ↗
Robert A. EckertDirector2026-05-19A66500CommonForm 4 ↗
Tyler JacksDirector2026-05-19A66500CommonForm 4 ↗
Mary E. KlotmanDirector2026-05-19A66500CommonForm 4 ↗
Ellen J. KullmanDirector2026-05-19A66500CommonForm 4 ↗
Wanda M. AustinDirector2026-05-19A66500CommonForm 4 ↗
S. Omar IshrakDirector2026-05-19A66500CommonForm 4 ↗
Michael V. DrakeDirector2026-05-19A66500CommonForm 4 ↗
Amy E. MilesDirector2026-05-19A66500CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Robert BradwayPSU2025-05-0631,00862,016$8,999,762
Robert BradwayRSU2025-05-0613,3113,599,827
Murdo GordonPSU2025-05-069,13018,2602,649,891
Murdo GordonRSU2025-05-063,9191,059,854
James BradnerRSU2025-05-063,549959,792
Robert BradwayOPTION2025-05-0686,0425,399,996
Murdo GordonOPTION2025-05-0625,3341,589,962
James BradnerPSU2025-05-068,26916,5382,399,995
James BradnerOPTION2025-05-0622,9441,439,965
Peter GriffithOPTION2025-05-0625,3341,589,962
Peter GriffithPSU2025-05-069,13018,2602,649,891
David ReesePSU2025-05-068,26916,5382,399,995
Peter GriffithRSU2025-05-063,9191,059,854
David ReeseOPTION2025-05-0622,9441,439,965
David ReeseRSU2025-05-063,549959,792
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Robert Bradway$3,599,827$8,999,762$5,399,99650.0%
Murdo Gordon1,059,8542,649,8911,589,96250.0%
James Bradner959,7922,399,9951,439,96550.0%
Peter Griffith1,059,8542,649,8911,589,96250.0%
David Reese959,7922,399,9951,439,96550.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Robert BradwayOption25,334270.44
Peter GriffithOption21,608235.97
Murdo GordonOption22,944270.44
Robert BradwayOption38,253230.92
Murdo GordonOption24,009235.97
Murdo GordonRSU17,3905,691,921
James BradnerRSU14,1104,618,344
Murdo GordonOption22,930300.3
Peter GriffithRSU12,4984,090,720
David ReesePSU16,9435,545,613
Robert BradwayRSU42,65713,962,063
Murdo GordonOption12,020230.92
Peter GriffithPSU18,7076,122,988
Murdo GordonPSU16,9435,545,613
David ReeseRSU15,7505,155,133
Robert BradwayRSU11,6693,819,380
Murdo GordonRSU11,2903,695,330
Peter GriffithOption25,334270.44
David ReeseOption22,944270.44
Robert BradwayRSU59,06719,333,220
David ReeseRSU30,4819,976,736
David ReeseOption21,608235.97
David ReeseOption10,818230.92
David ReeseOption20,767300.3
Peter GriffithOption10,818230.92
James BradnerOption18,603300.3
Robert BradwayOption76,407235.97
Robert BradwayOption77,877300.3
Murdo GordonRSU13,4034,386,936
Peter GriffithRSU12,0633,948,341
David ReeseRSU12,0633,948,341
Peter GriffithOption20,767300.3
Robert BradwayPSU18,7076,122,988
Peter GriffithRSU15,7505,155,133
05

Incentive-plan design — the Compensation Discussion & Analysis

Pay for performance in a manner that strongly aligns with stockholder interests by rewarding both our short- and long-term performance. Drive our business strategy by positioning our staff to execute on our strategic priorities in the near- and longer-term with a mix of incentives and targets (financial and operational) that are tied to near- and long-term performance periods and activities. Attract, motivate, and retain the highest level of talent by providing competitive compensation, consistent with their roles and responsibilities, our success, and their contributions to this success.

CEO STI target (% of salary)150%
CEO LTI target (% of salary)
Independent consultantFrederic W. Cook & Co., Inc. (FW Cook)
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-19399,315,38111,987,6821,636,40496.7%Passed
20252025-05-23381,269,28121,382,0501,909,34394.24%Passed
20242024-05-31372,548,83624,800,7401,433,59093.42%Passed
20232023-05-19371,994,64223,910,0862,582,26093.35%Passed
20222022-05-17357,838,92740,742,4501,868,53989.36%Passed
20212021-05-18405,071,77427,384,2202,624,36793.1%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1996.7%a
20252025-05-2394.24%b
20242024-05-3193.42%c

a. Approved under the standard stated in the filing — “Abstentions will have the same effect as votes "against" each proposal.”.

b. Approved under the standard stated in the filing — “Abstentions will have the same effect as votes "against" each proposal.”.

c. Approved under the standard stated in the filing — “Abstentions will have the same effect as votes "against" each proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)160 : 1
CEO total compensation$24,693,120
Median employee compensation$154,123
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Robert A. EckertIndependent · Lead Independent Director · Governance and Nominating · Compensation$210,000$219,773$0$0$20,134$449,907
Ellen J. KullmanIndependent · Governance and Nominating · Compensation (Chair)160,000219,7730020,395400,168
Greg C. GarlandIndependent · Governance and Nominating (Chair)160,000219,7730020,123399,896
Charles M. Holley JrIndependent · Governance and Nominating · Audit (Chair)389,77303,913393,686
S. Omar IshrakIndependent · Audit · Compensation359,7730020,708380,481
Tyler JacksIndependent · Compliance140,000219,7730020,352380,125
Brian J. DrukerIndependent · Compliance140,000219,7730020,137379,910
Mary E. KlotmanIndependent · Governance and Nominating · Compliance140,000219,7730020,131379,904
Amy E. MilesIndependent · Governance and Nominating · Audit140,000219,7730020,123379,896
Wanda M. AustinIndependent · Audit140,000219,7730010,134369,907
Michael V. DrakeIndependent · Governance and Nominating · Compliance359,773007,711367,484
Robert A. BradwayEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$140,000
Annual equity retainer$219,773
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,230,000
Equity awards (grant-date value)$2,867,503
All other compensation$183,861
Total cost of the board$4,281,364

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Amgen Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Amgen Inc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Eli Lilly and Company2025David Ricks$1,700,000$23,325,000$0$6,485,500$36,698,337
2Johnson & Johnson2025Joaquin Duato1,600,00015,028,9485,927,9954,298,70032,758,111
3AbbVie Inc.2025Robert Michael1,700,00013,268,4563,199,1545,200,00032,530,984
4Gilead Sciences, Inc.2025Daniel O'Day1,795,19215,238,4024,500,0604,848,12028,437,198
5Pfizer Inc.2025Albert Bourla1,800,0009,442,7058,998,1415,400,00027,585,301
6Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
7Biogen Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
8Bristol-Myers Squibb Company2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
9Vertex Pharmaceuticals Incorporated2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
10Merck & Co., Inc.2025Robert Davis1,645,30212,102,8383,380,0042,326,50020,797,845
11Regeneron Pharmaceuticals, Inc.2025Leonard Schleifer1,979,922003,682,6557,280,549
Novartis AGnot in coverage universe
Sanofi S.A.not in coverage universe
GlaxoSmithKline plcnot in coverage universe
AstraZeneca plcnot in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
AbbVie Inc.not disclosedPSU 40 · RSU 40 · Options 20Yes — Relative TSRSemler Brossy
AstraZeneca plcnot disclosednot disclosednot disclosednot disclosed
Biogen Inc.127%PSU 60 · RSU 40YesPay Governance
Bristol-Myers Squibb Company157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
Eli Lilly and Company218%PSU 100NoFW Cook
Gilead Sciences, Inc.180%PSU 50 · Options 25 · RSU 25Yes — Relative TSRFW Cook
GlaxoSmithKline plcnot disclosednot disclosednot disclosednot disclosed
Johnson & Johnsonnot disclosednot disclosednot disclosedSemler Brossy Consulting Group
Merck & Co., Inc.94%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (R-TSR)FW Cook
Novartis AGnot disclosednot disclosednot disclosednot disclosed
Pfizer Inc.150%PSU 50 · MSU 50Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG)Meridian Compensation Partners, LLC
Regeneron Pharmaceuticals, Inc.155%Options 60 · RSA 40not disclosedPay Governance LLC
Sanofi S.A.not disclosednot disclosednot disclosednot disclosed
Vertex Pharmaceuticals Incorporatednot disclosedPSU 55 · RSU 45Nonot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Amgen Inc. in fiscal 2025?
As disclosed, the highest-paid executive at Amgen Inc. in fiscal 2025 was Robert Bradway, Chief Executive Officer and President, with total compensation of $24,693,120.
How does Amgen Inc.'s chief executive pay compare to its disclosed peer group?
The filing shows that Amgen Inc.'s chief executive pay falls at the 50th percentile of its disclosed peer group.
What is Amgen Inc.'s CEO-to-median employee pay ratio?
As disclosed, the CEO-to-median employee pay ratio was 160:1.
How did shareholders vote on Amgen Inc.'s executive compensation?
As disclosed, shareholders voted 96.7% in support of Amgen Inc.'s executive compensation.
How much does Amgen Inc. spend in total on board compensation for fiscal 2025?
The filing shows that Amgen Inc. spent $4,281,364 in total on board compensation for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Robert BradwayDEF 14A2026-04-070001193125-26-145588Section “Summary Compensation Table” · page 88. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
2Section 01, James BradnerDEF 14A2026-04-070001193125-26-145588Section “Summary Compensation Table”. As printed: 8,639,867. Filing ↗machine: span 1620977–1620986
3Section 01, Peter GriffithDEF 14A2026-04-070001193125-26-145588Section “Summary Compensation Table”. As printed: 8,610,887. Filing ↗machine: span 1598522–1598531
4Section 01, Murdo GordonDEF 14A2026-04-070001193125-26-145588Section “Summary Compensation Table”. As printed: 8,523,471. Filing ↗machine: span 1605907–1605916
5Section 01, David ReeseDEF 14A2026-04-070001193125-26-145588Section “Summary Compensation Table”. As printed: 8,290,308. Filing ↗machine: span 1613268–1613277
6Section 03, Robert Bradway PSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r6 · c43 · span 1716814–1716823
7Section 03, Robert Bradway RSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r7 · c43 · span 1719556–1719565
8Section 03, Murdo Gordon PSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r14 · c43 · span 1739416–1739425
9Section 03, Murdo Gordon RSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r15 · c43 · span 1742157–1742166
10Section 03, James Bradner RSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r23 · c43 · span 1764753–1764760
11Section 03, Robert Bradway OPTIONDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r8 · c43 · span 1722502–1722511
12Section 03, Murdo Gordon OPTIONDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r16 · c43 · span 1745103–1745112
13Section 03, James Bradner PSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r22 · c43 · span 1762012–1762021
14Section 03, James Bradner OPTIONDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r24 · c43 · span 1769429–1769438
15Section 03, Peter Griffith OPTIONDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r12 · c43 · span 1733753–1733762
16Section 03, Peter Griffith PSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r10 · c43 · span 1728116–1728125
17Section 03, David Reese PSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r18 · c43 · span 1750714–1750723
18Section 03, Peter Griffith RSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r11 · c43 · span 1730832–1730841
19Section 03, David Reese OPTIONDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r20 · c43 · span 1756349–1756358
20Section 03, David Reese RSUDEF 14A2026-04-070001193125-26-145588Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t464 · r19 · c43 · span 1753430–1753437
21Section 07, pay ratioDEF 14A2026-04-070001193125-26-145588Section “CEO Pay Ratio”. As printed: 160 : 1. Filing ↗machine: t16 · r2 · c1 · span 92660–92663
22Section 08, Robert A. EckertDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 449,907. Filing ↗machine: t567 · r6 · c15 · span 2364134–2364141
23Section 08, Ellen J. KullmanDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 400,168. Filing ↗machine: t567 · r12 · c15 · span 2374887–2374894
24Section 08, Greg C. GarlandDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 399,896. Filing ↗machine: t567 · r7 · c15 · span 2365907–2365914
25Section 08, Charles M. Holley JrDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 393,686. Filing ↗machine: t567 · r8 · c15 · span 2367755–2367762
26Section 08, S. Omar IshrakDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 380,481. Filing ↗machine: t567 · r9 · c15 · span 2369621–2369628
27Section 08, Tyler JacksDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 380,125. Filing ↗machine: t567 · r10 · c15 · span 2371365–2371372
28Section 08, Brian J. DrukerDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 379,910. Filing ↗machine: t567 · r5 · c15 · span 2362385–2362392
29Section 08, Mary E. KlotmanDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 379,904. Filing ↗machine: t567 · r11 · c15 · span 2373138–2373145
30Section 08, Amy E. MilesDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 379,896. Filing ↗machine: t567 · r13 · c15 · span 2377221–2377228
31Section 08, Wanda M. AustinDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 369,907. Filing ↗machine: t567 · r3 · c15 · span 2358770–2358777
32Section 08, Michael V. DrakeDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 367,484. Filing ↗machine: t567 · r4 · c15 · span 2360612–2360619
33Section 08, Robert A. BradwayDEF 14A2026-04-070001193125-26-145588Section “Director Compensation”. As printed: 0. Filing ↗
34Section 02, Murdo Gordon 2026-05-02Form 42026-05-050000318154-26-000061Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Matthew C. Busch 2026-05-02Form 42026-05-050000318154-26-000060Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Nancy A. Grygiel 2026-05-02Form 42026-05-050000318154-26-000064Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Esteban Santos 2026-05-02Form 42026-05-050000318154-26-000068Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Esteban Santos 2026-05-02Form 42026-05-050000318154-26-000068Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Peter Griffith 2026-05-02Form 42026-05-050000318154-26-000063Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Derek Miller 2026-05-02Form 42026-05-050000318154-26-000066Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Robert A. Bradway 2026-05-02Form 42026-05-050000318154-26-000058Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Robert A. Bradway 2026-05-02Form 42026-05-050000318154-26-000058Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Nancy A. Grygiel 2026-05-02Form 42026-05-050000318154-26-000064Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Rachna Khosla 2026-05-02Form 42026-05-050000318154-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, David Reese 2026-05-02Form 42026-05-050000318154-26-000067Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Jonathan P. Graham 2026-05-02Form 42026-05-050000318154-26-000062Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, David Reese 2026-05-02Form 42026-05-050000318154-26-000067Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Derek Miller 2026-05-02Form 42026-05-050000318154-26-000066Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Rachna Khosla 2026-05-02Form 42026-05-050000318154-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Peter Griffith 2026-05-02Form 42026-05-050000318154-26-000063Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Jonathan P. Graham 2026-05-02Form 42026-05-050000318154-26-000062Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Murdo Gordon 2026-05-02Form 42026-05-050000318154-26-000061Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Matthew C. Busch 2026-05-02Form 42026-05-050000318154-26-000060Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Nancy A. Grygiel 2026-05-02Form 42026-05-050000318154-26-000064Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Derek Miller 2026-05-05Form 42026-05-070000318154-26-000074Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, David Reese 2026-05-05Form 42026-05-070000318154-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Esteban Santos 2026-05-05Form 42026-05-070000318154-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Charles M. Holley Jr 2026-05-05Form 42026-05-070000318154-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Murdo Gordon 2026-05-05Form 42026-05-070000318154-26-000079Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, James Bradner 2026-05-05Form 42026-05-070000318154-26-000082Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Jonathan P. Graham 2026-05-05Form 42026-05-070000318154-26-000078Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Jonathan P. Graham 2026-05-05Form 42026-05-070000318154-26-000078Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Peter Griffith 2026-05-05Form 42026-05-070000318154-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Rachna Khosla 2026-05-05Form 42026-05-070000318154-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Derek Miller 2026-05-05Form 42026-05-070000318154-26-000074Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Derek Miller 2026-05-05Form 42026-05-070000318154-26-000074Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, David Reese 2026-05-05Form 42026-05-070000318154-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, David Reese 2026-05-05Form 42026-05-070000318154-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Esteban Santos 2026-05-05Form 42026-05-070000318154-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Esteban Santos 2026-05-05Form 42026-05-070000318154-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, S. Omar Ishrak 2026-05-05Form 42026-05-070000318154-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, James Bradner 2026-05-05Form 42026-05-070000318154-26-000082Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Robert A. Bradway 2026-05-05Form 42026-05-070000318154-26-000081Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Matthew C. Busch 2026-05-05Form 42026-05-070000318154-26-000080Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Murdo Gordon 2026-05-05Form 42026-05-070000318154-26-000079Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Murdo Gordon 2026-05-05Form 42026-05-070000318154-26-000079Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Peter Griffith 2026-05-05Form 42026-05-070000318154-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Peter Griffith 2026-05-05Form 42026-05-070000318154-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Nancy A. Grygiel 2026-05-05Form 42026-05-070000318154-26-000076Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Robert A. Bradway 2026-05-05Form 42026-05-070000318154-26-000081Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, James Bradner 2026-05-05Form 42026-05-070000318154-26-000082Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Rachna Khosla 2026-05-05Form 42026-05-070000318154-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Michael V. Drake 2026-05-05Form 42026-05-070000318154-26-000069Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Matthew C. Busch 2026-05-05Form 42026-05-070000318154-26-000080Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Matthew C. Busch 2026-05-05Form 42026-05-070000318154-26-000080Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Robert A. Bradway 2026-05-05Form 42026-05-070000318154-26-000081Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Jonathan P. Graham 2026-05-05Form 42026-05-070000318154-26-000078Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Nancy A. Grygiel 2026-05-05Form 42026-05-070000318154-26-000076Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Nancy A. Grygiel 2026-05-05Form 42026-05-070000318154-26-000076Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Rachna Khosla 2026-05-05Form 42026-05-070000318154-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Murdo Gordon 2026-05-07Form 42026-05-110000318154-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, David Reese 2026-05-07Form 42026-05-110000318154-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Matthew C. Busch 2026-05-07Form 42026-05-110000318154-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Rachna Khosla 2026-05-07Form 42026-05-110000318154-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Nancy A. Grygiel 2026-05-07Form 42026-05-110000318154-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Robert A. Bradway 2026-05-07Form 42026-05-110000318154-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Derek Miller 2026-05-07Form 42026-05-110000318154-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Peter Griffith 2026-05-07Form 42026-05-110000318154-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, James Bradner 2026-05-07Form 42026-05-110000318154-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Esteban Santos 2026-05-07Form 42026-05-110000318154-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Jonathan P. Graham 2026-05-07Form 42026-05-110000318154-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Charles M. Holley Jr 2026-05-19Form 42026-05-210000318154-26-000103Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Greg C. Garland 2026-05-19Form 42026-05-210000318154-26-000102Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Brian J. Druker 2026-05-19Form 42026-05-210000318154-26-000100Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Robert A. Eckert 2026-05-19Form 42026-05-210000318154-26-000101Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Tyler Jacks 2026-05-19Form 42026-05-210000318154-26-000105Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Mary E. Klotman 2026-05-19Form 42026-05-210000318154-26-000106Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Ellen J. Kullman 2026-05-19Form 42026-05-210000318154-26-000107Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Wanda M. Austin 2026-05-19Form 42026-05-210000318154-26-000098Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, S. Omar Ishrak 2026-05-19Form 42026-05-210000318154-26-000104Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Michael V. Drake 2026-05-19Form 42026-05-210000318154-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Amy E. Miles 2026-05-19Form 42026-05-210000318154-26-000108Insider equity transaction reported since the proxy statement. Filing ↗
113Section 06, 2026 voteForm 8-K2026-05-200001193125-26-232786Item 5.07 · say-on-pay result. As reported: 96.7% (votes for as printed: 399,315,381). Filing ↗
114Section 06, 2025 voteForm 8-K2025-05-270000950170-25-077233Item 5.07 · say-on-pay result. As reported: 94.24% (votes for as printed: 381,269,281). Filing ↗
115Section 06, 2024 voteForm 8-K2024-06-030001193125-24-153221Item 5.07 · say-on-pay result. As reported: 93.42% (votes for as printed: 372,548,836). Filing ↗
116Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
117Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
118Section 09b board cost (computed)ComputedcomputedCash 1,230,000 + equity 2,867,503 + all other 183,861 = 4,281,364, summed across the director compensation table rows.machine: formula: Σ = 4,281,364
119Eli Lilly and Company, Section 10b CEO totalDEF 14A2026-03-200000059478-26-000029CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024
120Johnson & Johnson, Section 10b CEO totalDEF 14A2026-03-110000200406-26-000063CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246
121AbbVie Inc., Section 10b CEO totalDEF 14A2026-03-230001104659-26-033387CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. Filing ↗machine: t210 · r9 · c26 · span 1414083–1414093
122Gilead Sciences, Inc., Section 10b CEO totalDEF 14A2026-03-200001308179-26-000106CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
123Pfizer Inc., Section 10b CEO totalDEF 14A2026-03-120000078003-26-000033CEO total compensation as printed in Pfizer Inc.'s own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835
124Amgen Inc. (subject), Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
125Biogen Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
126Bristol-Myers Squibb Company, Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
127Vertex Pharmaceuticals Incorporated, Section 10b CEO totalDEF 14A2026-04-020000875320-26-000153CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809
128Merck & Co., Inc., Section 10b CEO totalDEF 14A2026-04-080001193125-26-147704CEO total compensation as printed in Merck & Co., Inc.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022
129Regeneron Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001308179-26-000340CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989
130Section 10a, Pfizer Inc. reciprocityDEF 14A0000078003-26-000033Pfizer Inc. names Amgen Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
131Section 10a, Eli Lilly and Company reciprocityDEF 14A0000059478-26-000029Eli Lilly and Company names Amgen Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
132Section 10a, Merck & Co., Inc. reciprocityDEF 14A0001193125-26-147704Merck & Co., Inc. names Amgen Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
133Section 10a, Vertex Pharmaceuticals Incorporated reciprocityDEF 14A0000875320-26-000153Vertex Pharmaceuticals Incorporated names Amgen Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
134Section 10a, AbbVie Inc. reciprocityDEF 14A0001104659-26-033387AbbVie Inc. names Amgen Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
135Section 10a, Johnson & Johnson reciprocityDEF 14A0000200406-26-000063Johnson & Johnson names Amgen Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
136Section 10a, Regeneron Pharmaceuticals, Inc. reciprocityDEF 14A0001308179-26-000340Regeneron Pharmaceuticals, Inc. names Amgen Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
137Section 10a, Gilead Sciences, Inc. reciprocityDEF 14A0001308179-26-000106Gilead Sciences, Inc. names Amgen Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
138Section 10a, Bristol-Myers Squibb Company reciprocityDEF 14A0000014272-26-000006Bristol-Myers Squibb Company names Amgen Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗